Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
Although many approaches have been used to treat hepatocellular carcinoma (HCC), the clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have focused on immunotherapy for HCC. Immunotherapies have shown promising clinical outcomes in several types of cancers a...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.589680/full |
| _version_ | 1818859336693186560 |
|---|---|
| author | Cheng Zhong Cheng Zhong Yirun Li Yirun Li Jing Yang Jing Yang Shengxi Jin Shengxi Jin Guoqiao Chen Guoqiao Chen Duguang Li Duguang Li Xiaoxiao Fan Xiaoxiao Fan Xiaoxiao Fan Hui Lin Hui Lin |
| author_facet | Cheng Zhong Cheng Zhong Yirun Li Yirun Li Jing Yang Jing Yang Shengxi Jin Shengxi Jin Guoqiao Chen Guoqiao Chen Duguang Li Duguang Li Xiaoxiao Fan Xiaoxiao Fan Xiaoxiao Fan Hui Lin Hui Lin |
| author_sort | Cheng Zhong |
| collection | DOAJ |
| description | Although many approaches have been used to treat hepatocellular carcinoma (HCC), the clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have focused on immunotherapy for HCC. Immunotherapies have shown promising clinical outcomes in several types of cancers and potential therapeutic effects for advanced HCC. In this review, we summarize the immune tolerance and immunotherapeutic strategies for HCC as well as the main challenges of current therapeutic approaches. We also present alternative strategies for overcoming these limitations. |
| first_indexed | 2024-12-19T09:10:34Z |
| format | Article |
| id | doaj.art-56e7a82fa0124af2a14a61d2178cb044 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-19T09:10:34Z |
| publishDate | 2021-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-56e7a82fa0124af2a14a61d2178cb0442022-12-21T20:28:12ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-03-011110.3389/fonc.2021.589680589680Immunotherapy for Hepatocellular Carcinoma: Current Limits and ProspectsCheng Zhong0Cheng Zhong1Yirun Li2Yirun Li3Jing Yang4Jing Yang5Shengxi Jin6Shengxi Jin7Guoqiao Chen8Guoqiao Chen9Duguang Li10Duguang Li11Xiaoxiao Fan12Xiaoxiao Fan13Xiaoxiao Fan14Hui Lin15Hui Lin16Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBiomedical Research Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaDepartment of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBiomedical Research Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaDepartment of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBiomedical Research Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaDepartment of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBiomedical Research Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaDepartment of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBiomedical Research Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaDepartment of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBiomedical Research Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaDepartment of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBiomedical Research Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaState Key Laboratory of Modern Optical Instrumentations, Centre for Optical and Electromagnetic Research, College of Optical Science and Engineering, International Research Center for Advanced Photonics, Zhejiang University, Hangzhou, ChinaDepartment of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBiomedical Research Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaAlthough many approaches have been used to treat hepatocellular carcinoma (HCC), the clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have focused on immunotherapy for HCC. Immunotherapies have shown promising clinical outcomes in several types of cancers and potential therapeutic effects for advanced HCC. In this review, we summarize the immune tolerance and immunotherapeutic strategies for HCC as well as the main challenges of current therapeutic approaches. We also present alternative strategies for overcoming these limitations.https://www.frontiersin.org/articles/10.3389/fonc.2021.589680/fullimmunotherapyhepatocellular carcinomaimmune tolerancetumor mutational burdentumor microenvironmentepigenetic modification |
| spellingShingle | Cheng Zhong Cheng Zhong Yirun Li Yirun Li Jing Yang Jing Yang Shengxi Jin Shengxi Jin Guoqiao Chen Guoqiao Chen Duguang Li Duguang Li Xiaoxiao Fan Xiaoxiao Fan Xiaoxiao Fan Hui Lin Hui Lin Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects Frontiers in Oncology immunotherapy hepatocellular carcinoma immune tolerance tumor mutational burden tumor microenvironment epigenetic modification |
| title | Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects |
| title_full | Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects |
| title_fullStr | Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects |
| title_full_unstemmed | Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects |
| title_short | Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects |
| title_sort | immunotherapy for hepatocellular carcinoma current limits and prospects |
| topic | immunotherapy hepatocellular carcinoma immune tolerance tumor mutational burden tumor microenvironment epigenetic modification |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.589680/full |
| work_keys_str_mv | AT chengzhong immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects AT chengzhong immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects AT yirunli immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects AT yirunli immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects AT jingyang immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects AT jingyang immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects AT shengxijin immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects AT shengxijin immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects AT guoqiaochen immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects AT guoqiaochen immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects AT duguangli immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects AT duguangli immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects AT xiaoxiaofan immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects AT xiaoxiaofan immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects AT xiaoxiaofan immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects AT huilin immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects AT huilin immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects |